Index falls as earnings results weigh; pound above $1.33, Bodycote soars
Celestica Inc (NYSE:CLS) stock reached an all-time high of 165.5 USD, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" overall financial health score, though current valuations suggest the stock is trading above its Fair Value. This achievement comes as the stock has experienced a remarkable 1-year change, with its value increasing by 156.42%. The surge in Celestica (TSX:CLS)’s stock price underscores the company’s robust performance and investor confidence over the past year, supported by strong revenue growth of 21% and a healthy return on equity of 26%. This upward trajectory highlights Celestica’s strong market position and potential for continued growth in the competitive tech industry. Analysts maintain a bullish outlook, with seven analysts recently revising earnings estimates upward. For deeper insights and additional ProTips about CLS, including comprehensive valuation metrics and growth projections, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Celestica reported strong financial results for the first quarter of 2025, with earnings and revenue surpassing analyst expectations. The company posted adjusted earnings per share of $1.20, beating the estimate of $1.12, and achieved revenue of $2.65 billion, marking a 20% year-over-year increase. Despite this positive performance, Celestica’s stock experienced a decline, possibly due to guidance for the second quarter that was only modestly above consensus. The company raised its full-year 2025 revenue outlook to $10.85 billion and increased its adjusted EPS guidance to $5.00.
Stifel analysts maintained a Buy rating on Celestica, with a price target of $150, following the company’s announcement of its robust financial performance. BMO Capital Markets adjusted their price target on Celestica shares to $130, maintaining an Outperform rating, citing the company’s strong competitive position and significant contract wins. Previously, BMO Capital had reduced their price target to $118 from $140 due to industry-wide multiple compression, yet remained optimistic about Celestica’s prospects. Both firms highlight Celestica’s strategic wins and market strength, underlining a positive trajectory for the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.